𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma

✍ Scribed by Manzurul A. Sikder; Jonathan W. Friedberg

Book ID
107546629
Publisher
Current Science Inc.
Year
2008
Tongue
English
Weight
260 KB
Volume
10
Category
Article
ISSN
1523-3790

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment of B-cell non-Hodgkin's lympho
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi πŸ“‚ Article πŸ“… 2001 πŸ› Elsevier Science 🌐 English βš– 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have